Cargando…

Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype

Metastasis is a major cause of mortality and remains a hurdle in the search for a cure for cancer. Not much is known about metastatic cancer cells and endothelial cross-talk, which occurs at multiple stages during metastasis. Here we report a dynamic regulation of the endothelium by cancer cells thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Connor, Yamicia, Tekleab, Sarah, Nandakumar, Shyama, Walls, Cherelle, Tekleab, Yonatan, Husain, Amjad, Gadish, Or, Sabbisetti, Venkata, Kaushik, Shelly, Sehrawat, Seema, Kulkarni, Ashish, Dvorak, Harold, Zetter, Bruce, R. Edelman, Elazer, Sengupta, Shiladitya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697439/
https://www.ncbi.nlm.nih.gov/pubmed/26669454
http://dx.doi.org/10.1038/ncomms9671
Descripción
Sumario:Metastasis is a major cause of mortality and remains a hurdle in the search for a cure for cancer. Not much is known about metastatic cancer cells and endothelial cross-talk, which occurs at multiple stages during metastasis. Here we report a dynamic regulation of the endothelium by cancer cells through the formation of nanoscale intercellular membrane bridges, which act as physical conduits for transfer of microRNAs. The communication between the tumour cell and the endothelium upregulates markers associated with pathological endothelium, which is reversed by pharmacological inhibition of these nanoscale conduits. These results lead us to define the notion of ‘metastatic hijack': cancer cell-induced transformation of healthy endothelium into pathological endothelium via horizontal communication through the nanoscale conduits. Pharmacological perturbation of these nanoscale membrane bridges decreases metastatic foci in vivo. Targeting these nanoscale membrane bridges may potentially emerge as a new therapeutic opportunity in the management of metastatic cancer.